In addition, while anti-PD-1/PD-L1 blocking antibodies were proven similarly efficacious in B16 melanoma-bearing mice, even at elevated PD-L1 levels (37), the potency of anti-PD-L1 and not that of anti-PD-1 was found to decline with age in the B16 model (67). This evidence concerns the gene PDCD1 and melanoma.